His geriatric doctor said "no" to prescribing medication to help slow down the disease. The doctor said his pulse rate is low ...
Antimicrobials, vaccines, and anti-inflammatories associated with reduced risk for Alzheimer disease and dementia.
The Food and Drug Administration (FDA) has approved a new maintenance dosing schedule for Leqembi, a monoclonal antibody ...
Alzheimer's disease, a devastating neurodegenerative condition that impacts millions globally, may have found an unexpected ...
Access to the new Alzheimer's drugs is limited by strict eligibility criteria, long wait times, and a lack of infusion ...
Xenon is one of the six noble gases. Its name derives from the Greek word for “strange”. In medicine, it has been used as an ...
Lecanemab is a humanized immunoglobulin gamma 1 monoclonal antibody directed against aggregated soluble and insoluble forms of amyloid beta.
The FDA approves a new maintenance dosing regimen for lecanemab (Leqembi; Eisai) in patients with early-stage Alzheimer ...
With this approval, patients who receive the anti-amyloid drug biweekly for 18 months can then consider switching to a monthly dosing regimen.
There are two kinds of risk factors for dementia: non-modifiable and modifiable. Non-modifiable risk factors are ones that cannot be changed or eliminated, like aging, family history and genetics.
But a new mouse study shows one possible use case for xenon — as a treatment for Alzheimer’s disease. The paper, published Wednesday in Science Translational Medicine, shows the potential of ...
Medicines can help you manage, prevent, or end headache pain. There are many different treatment options available. Some medicines relieve headache pain, while others target underlying conditions ...